diagnosis | Page 34 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

diagnosis

ASH 2021 Updates: MDS and Secondary AML

In this webinar, Dr. Elizabeth Griffiths discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and secondary AML. These studies were presented at the American Society of Hematology (ASH) 2021 meeting in Atlanta, GA. Research findings are explained along with the potential impact of this research on understanding and treating MDS and AML. This is an advanced scientific presentation.

Living in an online world: Social media experiences of adolescents and young adults with cancer

Abstract
Background
Despite widespread use, little is known about how adolescents and young adults (AYA) with cancer use social media (SM). This research characterized use and self-reported SM experiences among AYA with cancer.

Procedure
AYA, aged 12-26 years, receiving cancer care completed a mixed-methods survey regarding SM experiences. Clinical information was obtained from the electronic medical record. Data were analyzed with descriptive statistics, t tests, and qualitative content analysis.

Zohra Nooruddin, MD

Nooruddin, Zohra
Mays Cancer Center at UT Health San Antonio MD Anderson

Zohra Nooruddin, MD received her medical degree from Ziauddin Medical University in Karachi, Pakistan, and attended Mount Sinai School of Medicine in Englewood, New Jersey for her residency. Dr. Nooruddin completed a fellowship in symptom control and palliative care at The University of Texas MD Anderson Cancer Center in Houston, and a fellowship in hematology-oncology at the University of Colorado Denver. She is board-certified in hospice and palliative medicine, and in hematology and oncology.

Anand Karnad, MD

Karnad, Anand
Mays Cancer Center at UT Health San Antonio MD Anderson

Dr. Anand Karnad received his medical degree from Madras Medical College at the University of Madras (Chennai), in India. Dr. Karnad is Chief, Division of Hematology-Oncology at the Department of Medicine, and UT Health San Antonio MD Anderson Cancer Center and has been Professor of Medicine here since 2004. He has been an active investigator for the National Cancer Institute Clinical Trials for two decades, including trials designed to prevent and treat a range of cancers. He is principal investigator for the National Clinical Trials System (NCTN) SWOG trials at the Cancer Center.